Thailand Antifungal Drugs Market Size & Outlook, 2023-2030
Thailand antifungal drugs market, 2018-2030 (US$M)
Related Markets
Thailand antifungal drugs market highlights
- The Thailand antifungal drugs market generated a revenue of USD 27.6 million in 2023 and is expected to reach USD 40.9 million by 2030.
- The Thailand market is expected to grow at a CAGR of 5.8% from 2024 to 2030.
- In terms of segment, azoles was the largest revenue generating drug class in 2023.
- Echinocandins is the most lucrative drug class segment registering the fastest growth during the forecast period.
Antifungal drugs market data book summary
| Market revenue in 2023 | USD 27.6 million |
| Market revenue in 2030 | USD 40.9 million |
| Growth rate | 5.8% (CAGR from 2023 to 2030) |
| Largest segment | Azoles |
| Fastest growing segment | Echinocandins |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Azoles, Echinocandins, Polyenes, Allylamines |
| Key market players worldwide | Novartis AG ADR, Pfizer Inc, Bayer AG, Sanofi SA, Merck KGaA, Merck & Co Inc, GlaxoSmithKline, Abbott Laboratories, Enzon Pharmaceuticals Inc, Astellas Pharma Inc, Glenmark Pharmaceuticals |
Other key industry trends
- In terms of revenue, Thailand accounted for 0.2% of the global antifungal drugs market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, Japan antifungal drugs market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 1,381.0 million by 2030.
Azoles was the largest segment with a revenue share of 47.46% in 2023. Horizon Databook has segmented the Thailand antifungal drugs market based on azoles, echinocandins, polyenes, allylamines covering the revenue growth of each sub-segment from 2018 to 2030.
The Thai FDA is responsible for ensuring quality, safety, and efficacy of health products in the country in accordance with national legislation & international agreements. The company must obtain a license from the Thai FDA to manufacture, sell, and import drugs in the country.
Japan Thailand has three types of public health insurance coverage: social security for eligible employees in private sector, universal coverage scheme for all citizens, and the civil service welfare system for central & local civil officers and their families.
The payment system for each reimbursement program is different from one another. The Comptroller General’s Department of the Ministry of Finance funds the civil service welfare system for central and local civil officers & their family insurance program and the National Health Security Office funds social security for eligible employees in private sector insurance programs under the National Health Security Act, BE 2545 (2002).
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antifungal Drugs Market Scope
Antifungal Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Thailand antifungal drugs market size, by drug class, 2018-2030 (US$M)
Thailand Antifungal Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
